Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Gastrofast Advance** is an oral combination drug used as an antacid and antireflux agent, mainly for the adjunctive treatment of gastroesophageal reflux, gastric hyperacidity, flatulence, and epigastric or retrosternal pain linked to acid reflux. It combines four active pharmaceutical ingredients: **magaldrate** (an antacid providing rapid and prolonged neutralization of gastric acid with a buffering effect, adjusting gastric pH to the optimal 3–5 range), **sodium alginate** (forms a durable "raft" barrier at the top of gastric contents, reducing acid reflux), **simethicone** (a non-systemic defoaming agent that decreases surface tension of gas bubbles, aiding in gas expulsion), and **sodium bicarbonate** (rapidly neutralizes gastric acidity and enhances the formation and buoyancy of the alginate "raft") [2][4][7]. It is primarily indicated for adult and pediatric patients (over 6 years) experiencing symptoms of gastroesophageal reflux and hyperacidity, including during pregnancy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gastrofast advance.